Ultrasound contrast agent hypersensitivity in patients allergic to polyethylene glycol: Position statement by the European Association of Cardiovascular Imaging

Roxy Senior, Jonathan R. Lindner, Thor Edvardsen, Bernard Cosyns

    Research output: Contribution to journalArticlepeer-review

    1 Scopus citations

    Abstract

    The Food and Drug Administration alert enhances our understanding of the mechanism of severe reactions to ultrasound-enhancing agents (UEAs). The known incidence of these reactions remains low and unchanged (1 in 10 000 administrations). Because the risk-tobenefit ratio for ultrasound contrast agents (UCAs) remains extremely low, we do not advise any changes to laboratory policy regarding indications for their use. The use of these agents should continue in situations where they have been shown to be impactful. Lipid-based UCAs (SonoVue and Luminity) are contraindicated in patients who have a history of prior hypersensitivity to these UEAs, to polyethylene glycol (PEG) (macrogol), or to PEG-containing products, such as certain bowel preps for colonoscopy or laxatives.

    Original languageEnglish (US)
    Pages (from-to)959-960
    Number of pages2
    JournalEuropean heart journal cardiovascular Imaging
    Volume22
    Issue number9
    DOIs
    StatePublished - Sep 1 2021

    Keywords

    • EACVI
    • hypersensitivity
    • position statement
    • ultrasound contrast agent

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging
    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Ultrasound contrast agent hypersensitivity in patients allergic to polyethylene glycol: Position statement by the European Association of Cardiovascular Imaging'. Together they form a unique fingerprint.

    Cite this